SI-BONE, Inc. (SIBN) - Q2 2025 10-Q Summary
Business Context and Reporting Period
SI-BONE, Inc. is a medical device company specializing in minimally invasive surgical implant systems for sacroiliac joint dysfunction and pelvic trauma. This report covers the quarterly period ended June 30, 2025. The company operates as a single reporting segment with revenue primarily derived from the United States (95.5% in Q2 2025).
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Revenue | $48.63 million | $39.97 million | $95.92 million | $77.84 million |
| Gross Profit | $38.81 million | $31.58 million | $76.50 million | $61.44 million |
| Gross Margin | 79.8% | 79.0% | 79.8% | 78.9% |
| Net Loss | $(6.15) million | $(8.94) million | $(12.69) million | $(19.84) million |
| Diluted EPS | $(0.14) | $(0.22) | $(0.30) | $(0.48) |
| Cash & Marketable Securities | $145.54 million (as of June 30, 2025) | |||
| Long-Term Debt | $35.51 million (net of issuance costs) | |||
| Operating Cash Flow (YTD) | $(4.74) million used |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 21.7% year-over-year in Q2 2025, driven primarily by a $8.6 million increase in U.S. revenue due to higher case volumes and an expanded product portfolio.
- Expense Management: Operating expenses increased 10.0% to $45.8 million. Sales and marketing expenses rose 6.3% due to higher commissions and headcount. General and administrative expenses increased 28.7%, largely due to higher personnel costs, stock-based compensation, and legal/consulting fees.
- Profitability: The net loss narrowed significantly to $6.15 million from $8.94 million in the prior year quarter, reflecting revenue growth outpacing expense increases.
- Inventory Build: Inventory increased to $34.2 million from $27.1 million at year-end 2024, reflecting strategic build-up for new product introductions.
Outlook, Risks, and Management Commentary
- Product Pipeline: The company continues to commercialize new products including iFuse INTRA and iFuse TORQ TNT (launched in 2024). Clinical trial results for the SAFFRON and STACI studies were published in 2025, showing positive outcomes for mobility recovery and pain reduction.
- Debt Refinancing: In November 2024, the company entered a Third Amendment to its Loan Agreement with First-Citizens Bank, extending the maturity date to September 1, 2029, and deferring the first principal payment to October 2027 (or 2028 upon achieving a performance milestone). The effective interest rate decreased to 7.3% in Q2 2025.
- Liquidity: Management believes existing cash and marketable securities ($145.5 million) are sufficient to fund operations for the next 12 months. However, the company has an accumulated deficit of $444.0 million and expects to incur additional losses in the future.
- Legal & Regulatory Risks:
- DOJ Investigation: The company received a Civil Investigative Demand (CID) in October 2024 regarding the Anti-Kickback Statute and False Claims Act related to meals and consulting payments. The outcome and financial impact are currently undetermined.
- Reimbursement: Uncertainty exists regarding CPT code definitions (27279 vs. 27278) effective January 2026, which could impact reimbursement rates and demand.
- Supply Chain: Risks include reliance on single-source suppliers for titanium and sterilization services, with potential impacts from geopolitical events and tariffs.
Investor Verification Checklist
- Verify the status and potential financial impact of the ongoing U.S. Department of Justice investigation regarding the Anti-Kickback Statute.
- Monitor the impact of the upcoming January 2026 CPT code definition changes on reimbursement rates for transfixing vs. non-transfixing procedures.
- Assess the company's ability to maintain gross margins above 79% amidst potential tariff increases on titanium and rising royalty costs.
- Review the "Performance Milestone" criteria in the Third Amended Loan Agreement that could defer principal payments to 2028.
- Track the conversion of inventory build-up into revenue, given the $7.2 million increase in inventory during the first half of 2025.